Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena Yu

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Cancer Discovery|May 15, 2015
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingPaul K Paik, Alexander Drilon, Pang-Dian Fan, et al.
Translational Lung Cancer Research|October 24, 2025
Radiomic phenotypes of oligometastatic non-small cell lung cancerKevin M Boehm, Emily S Lebow, N Ari Wijetunga, et al.
Neuro-Oncology Advances|January 7, 2022
Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasisN Ari Wijetunga, Adrienne Boire, Robert J Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung CancersJulia Rotow, Jyoti D Patel, Matthew P Hanley, et al.
The Lancet. Oncology|February 7, 2020
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, et al.
Blood|October 20, 2025
The Proteostasis Network is a Therapeutic Target in Acute Myeloid LeukemiaKentson Lam, Yoon Joon Kim, Evelyn Li-Ting Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2022
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal MetastasisJonathan T Yang, N Ari Wijetunga, Elena Pentsova, et al.
JCO Precision Oncology|October 30, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung CancerAlissa J Cooper, Benjamin Herzberg, Mitchell Parma, et al.
Nature Medicine|July 9, 2025
Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detectionGabriele Campanella, Neeraj Kumar, Swaraj Nanda, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Cancer Discovery|May 15, 2015
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingPaul K Paik, Alexander Drilon, Pang-Dian Fan, et al.
Translational Lung Cancer Research|October 24, 2025
Radiomic phenotypes of oligometastatic non-small cell lung cancerKevin M Boehm, Emily S Lebow, N Ari Wijetunga, et al.
Neuro-Oncology Advances|January 7, 2022
Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasisN Ari Wijetunga, Adrienne Boire, Robert J Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung CancersJulia Rotow, Jyoti D Patel, Matthew P Hanley, et al.
The Lancet. Oncology|February 7, 2020
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, et al.
Blood|October 20, 2025
The Proteostasis Network is a Therapeutic Target in Acute Myeloid LeukemiaKentson Lam, Yoon Joon Kim, Evelyn Li-Ting Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2022
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal MetastasisJonathan T Yang, N Ari Wijetunga, Elena Pentsova, et al.
JCO Precision Oncology|October 30, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung CancerAlissa J Cooper, Benjamin Herzberg, Mitchell Parma, et al.
Nature Medicine|July 9, 2025
Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detectionGabriele Campanella, Neeraj Kumar, Swaraj Nanda, et al.
Pageof 4